You are here: Home » Healthcare » Pharmaceuticals » GMP Chemistry Method Development » Lucideon Supports Wockhardt to get the COVID-19 Vaccine to Market
Lucideon Supports Wockhardt to get the COVID-19 Vaccine to Market
Lucideon was chosen by Wockhardt, the global pharmaceutical and biotechnology organisation, to support with testing of the COVID-19 vaccine.
Bringing to bear our product testing and process consultancy expertise, we tested part of the Wockhardt-manufactured fill finished vaccines, to verify that they were in specification and therefore fit for use.
Testing was carried out at Lucideon's global headquarters in Stoke-on-Trent, home to its Good Manufacturing Practice (GMP) testing laboratories and UK analytical chemistry facilities.
From there, Lucideon undertook extensive method development and validation for the chemical testing required for the vaccine to be released to the market.
Tony Kinsella, Chief Executive at Lucideon, said: "We are very proud to have worked with Wockhardt to ensure that vaccines were available to fight the Covid-19 pandemic.
"This work was of national and international significance and was carried out quickly and accurately.
"Effective regulatory compliance was essential to enable Wockhardt to get the vaccine doses to the market.
"We implemented new working patterns and made extra resource available at our pharmaceutical centre of excellence in Stoke-on-Trent to meet that need, and to produce results promptly and safely.
"As a global organisation, we are committed to working with our partners to fight coronavirus."